SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
| Valuation | |
|---|---|
| Market Cap ($M) | 105.57 |
| Enterprise Value ($M) | -65.03 |
| Book Value ($M) | 174.24 |
| Book Value / Share | 3.56 |
| Price / Book | 0.61 |
| NCAV ($M) | 155.35 |
| NCAV / Share | 3.18 |
| Price / NCAV | 0.68 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.55 |
| Return on Assets (ROA) | -0.41 |
| Return on Equity (ROE) | -0.44 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 8.11 |
| Current Ratio | 8.11 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 185.51 |
| Assets | 204.41 |
| Liabilities | 30.17 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Alger Associates Inc | 2.70 | -67.81 | |
| 13G/A | Jennison Associates Llc | 5.10 | -51.41 | |
| 13G/A | Prudential Financial Inc | 5.70 | -50.51 | |
| 13G/A | Venrock Healthcare Capital Partners III, L.P. | 3.30 | -37.96 | |
| 13G | T. Rowe Price Investment Management, Inc. | 7.50 | ||
| 13G/A | Adage Capital Management, L.P. | 7.43 | ||
| 13G/A | Vanguard Group Inc | 5.22 | 0.00 | |
| 13G/A | State Street Corp | 1.80 | -65.46 | |
| 13G | Bain Capital Life Sciences Opportunities III, LP | 5.70 | 38.04 | |
| 13G/A | Cormorant Asset Management, LP | 0.00 | -100.00 | |
| 13G/A | Commodore Capital Lp | 4.40 | 30.28 | |
| 13G/A | Lynx1 Capital Management LP | 4.99 | -24.29 | |
| 13G/A | Baker Bros. Advisors Lp | 3.40 | 8.45 | |
| 13G/A | Nichtberger Steven | 5.40 | 14.37 | |
| 13G/A | Flynn James E | 4.69 | -14.20 | |
| 13G/A | Adage Capital Partners Gp, L.l.c. | 9.47 | 50.99 | |
| 13G | BlackRock, Inc. | 10.30 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 373,834 | 1,363,619 | 27.41 | |
| 630,741 | 1,856,641 | 33.97 | |
| 463,134 | 1,637,832 | 28.28 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| BMEA – Biomea Fusion, Inc. | BMRN – BioMarin Pharmaceutical Inc. |
| BPMC – Blueprint Medicines Corporation | CCCC – C4 Therapeutics, Inc. |
| CGC – Canopy Growth Corporation |
Financial data and stock pages provided by
Fintel.io